Last week we introduced VERVE, a brand we invented for a category that didn't ask for it. Every quarter we pick a hard space, hand ourselves a real brief and a real deadline, and build the whole thing the way we'd build it for a paying client: strategy, identity, product, the lot. No client, no safety net, just the same pressure we feel every other day of the week. Last time we showed you the brand. This is the campaign: a sixty-second film made entirely from stock footage, for a GLP-1 companion app built to do the thing the category forgot to do.

About one in eight American adults has taken a GLP-1 — Ozempic, Wegovy, Mounjaro, Zepbound — and the number climbing toward them only goes up from here. The drugs work, dropping weight at a scale that until recently took surgery to achieve.

The trouble is that the drug is only ever half the story. Up to 40% of the weight lost can come from lean mass rather than fat when nobody intervenes with protein and resistance training, and the side effects nobody warns you about — nausea, fatigue, hair thinning — arrive on their own schedule. Then there's the part nobody mentions at the pharmacy: up to 70% of users stop within a year, and up to two-thirds of the weight returns when they do.

So the market shipped more diet apps. Calorie counters with a GLP-1 badge bolted on, all of them reaching for the same pale greens and clinical whites and the same interfaces built to log and subtract, because the drug suppresses appetite and the apps simply inherited its logic without ever asking whether it was the right one.

That's the gap. The medication creates the conditions for the body to change. Nobody built the thing that builds the person who has to live inside that change.

The numbers describe the problem without capturing it. To find what the campaign actually had to speak to, we went where GLP-1 users talk when no one's selling to them: the Reddit threads, the private Facebook groups, the comments running under the before-and-afters that collect the likes. The posts we were after were the other ones, the ones that don't get shared.

The picture that kept coming back went something like this. She's three months in, the scale is down twenty pounds, the compliments have started arriving — and she's standing in front of the bathroom mirror at seven in the morning, not unhappy exactly, but quietly unsettled, running her hands over a body that's smaller and somehow less hers.

The muscle went with the fat. Her energy disappeared around week four and never came back, and food, which used to be one of the uncomplicated pleasures of her week, is now a problem to be managed.

That's the tension the whole category steps around. She didn't want to disappear; she wanted to lose the weight and still feel like herself. Nobody in the space was willing to admit that the second part is the hard part.

We worked this brief inside Springboards, an AI platform built by ex-agency strategists for the messy reality of creative work rather than the tidy version most software assumes. The reason we keep reaching for it comes down to one design choice: where most AI narrows toward the single most likely answer, Springboards widens the field instead, handing you more territory than you'd reach on your own and getting you there faster.

That matters most at the start, when the brief is still soft and you're hunting for the angle nobody else has found. We mapped the category through its Brand Strategy and Insight Digger tools, then ran what we found through The Validator, which does the job a good strategist does and demands evidence before you fall for a line. Big Brand Ideas and Campaign Concepts gave us range to push against after that — provocations rather than answers. The value was never the tool handing us an idea. It was the tool refusing to let us settle on the first one, so the energy went into choosing and sharpening rather than into staring at a blank page.

What it kept circling back to was the distance between what the category says and what the audience carries. The category speaks in outcomes — weight lost, numbers down, progress logged — clinical facts the audience already half-knows. Underneath them sits the thing nobody says aloud, which isn't the fear of losing weight wrong but the fear of losing yourself in the process, of coming out the far side of treatment a stranger in your own body.

That distinction, between the clinical fact and the human fear beneath it, is the moment the brief became a campaign.

They gave you a prescription. Nobody gave you a plan.

The strategic bet behind "Lose Weight. Keep You." is that the loudest voice in this woman's life is the wrong one. The world cheers as the number drops. The compliments and the congratulations all land on the one metric the drug was always going to deliver, and none of it touches the quiet unease she feels looking at her own reflection. We wanted VERVE to be the first voice in the category that speaks to the unease instead of the applause.

That's why the whole first half withholds the product. The instinct in this category is to rush to the fix, but she is already drowning in fixes: quick advice, generic plans, a cacophony of voices that don't speak her language. Adding ours to that pile would have made us part of the noise. So the film holds its nerve and stays inside the problem. The scale where we never show the number. The message bubbles of advice she's already tried and already knows aren't enough. The body she's stopped recognising. It earns trust by proving it sees what she's actually going through, which is the one thing none of the quick-fixers bothered to do.

Then comes the real pivot, and it's a positional one. The entire category is built on diminishment, on less appetite and less food and less weight and less of you. VERVE starts from the opposite premise: that she isn't reacting to something happening to her body, she's authoring it. So when the product finally arrives, we don't keep it at the tasteful distance wellness advertising usually prefers. We show it building her. The treatment screen that already knows where she is in her injection cycle. The workout that's carried her goblet squat from 25 to 45lbs over eight weeks. The symptom check-in that meets "how are you feeling right now?" with knowledge rather than a platitude. Every screen is evidence of construction where the category only ever offered management, because the whole point is that VERVE leaves her stronger and more capable on the far side, not smaller and relieved to have survived a protocol.

Which is what the final frame argues. A woman holding the camera's eye, enlarged by the process rather than shrunk by it, under a line the rest of the category structurally cannot say:

More you. Every day.

Everyone else in this space sells less, because less is what the drug delivers and the marketing only ever learned to echo the pharmacology. "More" wasn't a clever inversion we reached for. It was the only honest thing left to promise once you decide the woman matters more than the number on her scale.

VERVE is a self-initiated spec project by Lento Agency. For work like this, get in touch.